# [18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)

> **NCT07723651** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 75 (estimated)

## Conditions studied

- Metastatic Prostate Cancer
- Prostate Cancer

## Interventions

- **DRUG:** 1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one
- **DEVICE:** FTT-PET/CT
- **DIAGNOSTIC_TEST:** EnhanceAR-Seq

## Key facts

- **NCT ID:** NCT07723651
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2032-03-31
- **Final completion:** 2032-03-31
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07723651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07723651, "[18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07723651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*